DelveInsight’s “IgA Nephropathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the IgA Nephropathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and China).
The report covers emerging IgA Nephropathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current IgA Nephropathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
IgA Nephropathy: An Overview
IgA Nephropathy (IgAN) is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. IgAN occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys.
IgAN is the most common glomerular disease worldwide but varies largely geographically. Studies assess the prevalence of IgAN in different regions and analyze factors responsible for geographic differences. According to one such prominent study, IgAN is more frequent in Asian populations (45 cases per million population in Japan) than in Caucasians (31 cases per million population/y in France).
IgA Nephropathy Market Key Facts
-
The total market size of IgA Nephropathy in the 7MM and China is approximately USD 500 million in 2022 and is projected to increase during the forecast period (2023–2032).
-
Among EU4 countries, Germany accounted for the maximum market size in 2022, while Spain occupied the bottom of the ladder.
-
There are no approved therapies for IgA Nephropathy in Japan and China, with current treatment being done primarily by ACE inhibitors/ARBs, immunosuppressants, and corticosteroids.
-
The total number of prevalent cases of IgA Nephropathy in the United States was around ~193,700 cases in 2022.
-
Among the EU4 countries, Germany accounted for the largest IgA Nephropathy prevalent cases, followed by France, whereas Spain accounted for the lowest number of prevalent cases in 2022.
-
According to DelveInsight estimates, there were ~1,414,000 prevalent cases of IgA Nephropathy in China in 2022, and the prevalence is projected to increase during the forecast period.
-
Japan accounted for about 88,000 diagnosed prevalent cases of IgA Nephropathy in 2022.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging IgA Nephropathy pipeline therapies. It also thoroughly assesses the IgA Nephropathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed IgA Nephropathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
IgA Nephropathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted IgA Nephropathy epidemiology trends in the seven major countries (7MM) + China from 2019 to 2032. It helps to recognize the causes of current and forecasted IgA Nephropathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the IgA Nephropathy Epidemiology, Segmented as –
-
Total Prevalent Cases of IgAN [2019–2032]
-
Gender-specific Cases of IgAN [2019–2032]
-
Age-specific Cases of IgA [2019–2032]
IgA Nephropathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the IgA Nephropathy market or expected to be launched during the study period. The analysis covers the IgA Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the IgA Nephropathy drugs based on their sale and market share.
The report also covers the IgA Nephropathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key IgA Nephropathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the IgA Nephropathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/iga-nephropathy-market
IgA Nephropathy Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for IgA Nephropathy. Currently, Travere Therapeutics is leading the therapeutics market with its IgA Nephropathy drug candidates in the most advanced stage of clinical development.
IgA Nephropathy Companies Actively Working in the Therapeutics Market Include
-
Aravive
-
Aduro BioTech
-
Alnylam Pharmaceuticals
-
Chinook Therapeutics
-
Transcenta Holding
-
Novartis Pharmaceuticals
-
Ionis Pharmaceuticals
-
Merck Serono
-
ZymoGenetics
And Many Others
Emerging and Marketed IgA Nephropathy Therapies Covered in the Report Include:
-
Atrasentan: Chinook Therapeutics
-
Sparsentan: Travere Therapeutics
-
Narsoplimab: Omeros Corporation
-
TARPEYO/ KINPEYGO (budesonide): Calliditas Therapeutics/STADA/Viatris/Everest Medicines
-
Iptacopan: Novartis Pharmaceuticals
-
BION-1301: Chinook Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/iga-nephropathy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. IgA Nephropathy Competitive Intelligence Analysis
4. IgA Nephropathy Market Overview at a Glance
5. IgA Nephropathy Disease Background and Overview
6. IgA Nephropathy Patient Journey
7. IgA Nephropathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. IgA Nephropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. IgA Nephropathy Unmet Needs
10. Key Endpoints of IgA Nephropathy Treatment
11. IgA Nephropathy Marketed Therapies
12. IgA Nephropathy Emerging Drugs and Latest Therapeutic Advances
13. IgA Nephropathy Seven Major Market + China Analysis
14. Attribute Analysis
15. IgA Nephropathy Market Outlook (In US, EU5, and Japan)
16. IgA Nephropathy Companies Active in the Market
17. IgA Nephropathy Access and Reimbursement Overview
18. KOL Views on the IgA Nephropathy Market
19. IgA Nephropathy Market Drivers
20. IgA Nephropathy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/iga-nephropathy-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Ankylosing Spondylitis (AS) Market
“Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Ankylosing Spondylitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Ankylosing Spondylitis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/